[43] suggested that pharmacological blockade of CCR2 and its antagonists could affect the infiltration of mast cells and other inflammatory cells into human AAA lesions, potentially preventing or reducing AAA formation or progression. The gene discussed is CCR2; the disease is triple-A syndrome.